Comparative analysis between ethinyl estradiol & cyperoterone acetate with or without metformin therapy in the treatment of polycyctic ovarian syndrome induced hirsutism
DOI:
https://doi.org/10.66344/jpad.v16i2.854Keywords:
Hirsutism, polycystic ovarian syndrome (PCOS), metformin, cyproterone acetateAbstract
Background Children up to 15 years of age constitute a major portion of our population and do suffer from a wide variety of skin diseases. Pediatric dermatology is a separate subspecialty by itself hitherto non-existing in Pakistan. The current work focuses on the audit of pediatric dermatological cases presenting in the outpatient department of Dermatology and Pediatrics, Hamdard University Hospital, Karachi, during the calendar year 2005.
Objective The current audit emphasizes the importance of separate pediatric dermatology setups.
Patients and methods All patients aged below 15 years, belonging to both sexes suffering from dermatological diseases were included in the study. After a detailed history and clinical examination, a clinical diagnosis was made in each case. The patients enrolled were investigated, as well.
Results A total of 830 cases of pediatric dermatology, 539 males (65%) and 291 females (35%) were seen during the calendar year 2005, accounting for 27.2% of all dermatological patients. The age range was 0.1-15 years with a mean age of 8.1 years. Scabies (24.5%) was the most common dermatosis reported followed by atopic eczema (16.3%), fungal infections (15.9%), urticaria (12.3%) and bacterial infections (9.5%). Hair loss (alopecia), pityriasis alba, vitiligo and a few miscellaneous disorders had a comparatively low frequency.
Conclusion Scabies remains the most common pediatric dermatosis followed by fungal infections, atopic eczema, urticaria and bacterial infections.
References
Conway GS, Honour JW, Jacobs HS.
Heterogeneity of the polycystic ovary
syndrome. Clinical, endocrine and
ultrasound features in 556 patients.
Clinical Endocrinology 1989; 30: 459-
Adams J, Polson DW, Franks S.
Prevalence of polycystic ovaries in
women with anovulation and idiopathic
hirsutism. Br Med J 1986; 293:355-9.
Ehrmann DA. Polycystic ovary
syndrome. N Engl J Med 2005; 3552:
-36.
Rotterdaam ESHRE/ASRM-sponsored
PCOS consensus workshop group.
Revised 2003 consensus on diagnostic
criteria and long term health risks related to polycystic ovary syndrome.
Fertil Steril 2003; 81: 19-25.
Legro R, Strauss J. Molecular progress
in infertility: polycystic ovary
syndrome. Fertil Steril 2003; 78: 569-
Dunaif A. Insulin resistance and the
polycystic ovarian syndrome:
mechanisms and implications for the
pathogenesis. Endocrine Rev 1997; 18:
-800.
Orio Jr F, Lucidi P, Palomba S et al.
Circulating ghrelin concentrations in the
polycystic ovary syndrome. J Clin
Endocrinol Metab 2003; 88:942-45.
Sharma A, Yousaf M, Rianna B. Recent
developments in polycystic ovary
syndrome. Progress in Obstetrics and
Gynaecology 2005; 16: 227-39.
Homburg R. Polycystic ovary syndrome
in the adolescence. New insights in
pathophysiology and treatment 2005; 8:
-49.
Mekenna T. Cyproterone acetate in the
treatment of hirsutism. Clinical
Endocrinology 2005; 35: 5-10.
Lord JM, Flight IHK, Norman RJ.
Metformin in polycystic ovary
syndrome: systemic review and metaanalysis.
Br Med J 2003; 3227: 951-56.
Aurana J, Mittal S, Kumar S et al.
Metformin therapy in women with
polycystic ovary syndrome. Int J
Gynaecol Obstet 2004; 87: 237-41.
Troncoso G, Parra A. Insulin sensitizing
drugs increase the endogenous
dopaminergic tone in obese insulinresistant
women with polycystic ovary
syndrome. J Endocrinol 2005; 184:
-39.
Lord J, Wilkin T. Metformin in
polycystic ovary syndrome. Curr Opin
Obstet Gynaecol 2004; 16: 481-86.
Muth S, Norman J, Sattar N, Fleming R.
Women with polycystic ovary
syndrome often undergo protracted
treatment with metformin and are
disinclined to stop: indications for a
change in licensing arrangements. Hum
Reprod 2004; 19: 2718-20.
Downloads
Published
Issue
Section
License
Copyright (c) 2017 Aesha Sadaf Hameed, Rizwan Ahmad Malik, Jameel Ahmad Shaheen
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
